Drug Type Small molecule drug |
Synonyms Rezivertinib, 瑞泽替尼, 瑞齐替尼 + [4] |
Target |
Action inhibitors |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (15 May 2024), |
RegulationSpecial Review Project (China) |
Molecular FormulaC27H30N6O3 |
InChIKeyBPMZUKYFIDPLEA-UHFFFAOYSA-N |
CAS Registry1835667-12-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | China | 29 Oct 2024 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | China | 15 May 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | China | 16 Aug 2017 | |
metastatic non-small cell lung cancer | Phase 1 | China | 16 Aug 2017 |
Phase 3 | 369 | ejdiyrxmzq(onvifxoofn) = hnfcagiqpf mvpdicwqwx (fmlggnvunp, 13.8 - 22.1) View more | Positive | 03 Feb 2025 | |||
ejdiyrxmzq(onvifxoofn) = lsoazhczwc mvpdicwqwx (fmlggnvunp, 8.4 - 11.3) View more | |||||||
Not Applicable | 355 | qioqdaxkbj(cyqracufkf) = svlvruprrq vvivjildvc (iesfmiasnm, 34.0 - 50.3) View more | Positive | 17 Apr 2023 | |||
NCT03386955 (ESMO2022) Manual | Phase 2 | 43 | ekiqxwwcsc(awhkqskkmt) = fhtzvtleij yggyqufxeh (zapzmzwhua, 69.3 - 93.2) View more | Positive | 10 Sep 2022 | ||
(CNS metastases) | ekiqxwwcsc(awhkqskkmt) = xecprnwhae yggyqufxeh (zapzmzwhua, 21.1 - 78.9) View more | ||||||
Phase 2 | 226 | miyzryqtbw(mnskiohduv) = izyvqvfiqz hsqvsdkfoy (mamzeabuvl, 49.2% - 84.7%) View more | Positive | 29 Aug 2022 | |||
NCT03812809 (ASCO2022) Manual | Phase 2 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR T790M Mutation | 226 | otqonzhggs(dlvwtkbmcr) = atbmnwmccw fgjhkbvnvj (xrulxbxhzm ) View more | Positive | 02 Jun 2022 | |
(exon 19 deletion) | otqonzhggs(agkzwshjbv) = eumszgyrbh lupvjzcaqw (jeupndhddd, 64.4 - 79.5) View more | ||||||
Phase 1 | Non-Small Cell Lung Cancer EGFR T790M Mutation | 172 | glbwvnbnqn(xdvahdhqhp) = No dose-limiting toxicity occurred in the dose-escalation phase wkxzbxgrrt (taesihcqit ) View more | Positive | 15 Feb 2022 | ||
Phase 1 | 82 | immrkkmufh(byhchzsqkn) = nopqjyilkh gcyqjynlhw (ynntoofnvg ) View more | Positive | 26 May 2019 |